Amgen seen raising bid to acquire Onyx Pharmaceuticals: report

(Reuters) – Amgen Inc is expected to sweeten its offer to acquire Onyx Pharmaceuticals Inc to $130 per share after its previous bid was rejected as too low, Bloomberg reported on Tuesday, citing a person familiar with the matter. After Amgen’s unsolicited offer of $120 per share was turned down, Onyx said in June it was seeking takeover bids from other potential buyers. The $130 offer is currently the highest bid on the table for Onyx, according the anonymous source, the report said. A spokeswoman for Amgen, the world’s largest biotechnology company, declined to comment on the report. …